BioNTech SE (NASDAQ:BNTX) Sees Large Decrease in Short Interest

BioNTech SE (NASDAQ:BNTXGet Free Report) saw a significant decrease in short interest during the month of May. As of May 31st, there was short interest totalling 3,040,000 shares, a decrease of 11.1% from the May 15th total of 3,420,000 shares. Approximately 1.3% of the company’s stock are sold short. Based on an average daily volume of 741,300 shares, the short-interest ratio is currently 4.1 days.

BioNTech Price Performance

BNTX traded down $3.64 on Monday, reaching $88.44. The company had a trading volume of 1,237,800 shares, compared to its average volume of 708,242. The business has a 50 day simple moving average of $92.81 and a 200 day simple moving average of $95.75. The company has a market cap of $21.02 billion, a price-to-earnings ratio of 176.88 and a beta of 0.27. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.16 and a current ratio of 11.38. BioNTech has a 52-week low of $85.21 and a 52-week high of $125.83.

BioNTech (NASDAQ:BNTXGet Free Report) last announced its earnings results on Monday, May 6th. The company reported ($1.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.60). The company had revenue of $203.69 million during the quarter, compared to analysts’ expectations of $589.96 million. BioNTech had a net margin of 4.01% and a return on equity of 0.55%. As a group, sell-side analysts anticipate that BioNTech will post -2.01 EPS for the current year.

Wall Street Analysts Forecast Growth

BNTX has been the subject of a number of research analyst reports. Evercore ISI initiated coverage on shares of BioNTech in a report on Tuesday, May 14th. They set an “inline” rating and a $100.00 price objective for the company. UBS Group decreased their price objective on shares of BioNTech from $110.00 to $101.00 and set a “neutral” rating for the company in a report on Wednesday, March 27th. Canaccord Genuity Group restated a “buy” rating and set a $171.00 price objective on shares of BioNTech in a report on Thursday, March 21st. BMO Capital Markets cut their target price on shares of BioNTech from $123.00 to $122.00 and set an “outperform” rating for the company in a research report on Tuesday, May 7th. Finally, JPMorgan Chase & Co. cut their target price on shares of BioNTech from $99.00 to $90.00 and set an “underweight” rating for the company in a research report on Friday, March 22nd. One analyst has rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, BioNTech currently has a consensus rating of “Hold” and a consensus target price of $111.70.

View Our Latest Report on BioNTech

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. CWM LLC raised its stake in shares of BioNTech by 657.6% during the fourth quarter. CWM LLC now owns 250 shares of the company’s stock worth $26,000 after acquiring an additional 217 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of BioNTech by 121.0% in the first quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock worth $25,000 after buying an additional 150 shares during the period. Frazier Financial Advisors LLC purchased a new position in shares of BioNTech in the fourth quarter worth $30,000. Covestor Ltd purchased a new position in shares of BioNTech in the third quarter worth $32,000. Finally, First Horizon Advisors Inc. purchased a new position in shares of BioNTech in the fourth quarter worth $38,000. 15.52% of the stock is owned by hedge funds and other institutional investors.

BioNTech Company Profile

(Get Free Report)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

See Also

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.